These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
189 related items for PubMed ID: 15887248
1. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. Bai VU, Cifuentes E, Menon M, Barrack ER, Reddy GP. J Cell Physiol; 2005 Aug; 204(2):381-7. PubMed ID: 15887248 [Abstract] [Full Text] [Related]
2. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Quéro L, Giocanti N, Hennequin C, Favaudon V. Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473 [Abstract] [Full Text] [Related]
3. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S, Agoulnik IU, Weigel NL. Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350 [Abstract] [Full Text] [Related]
4. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA. Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446 [Abstract] [Full Text] [Related]
5. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J. Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040 [Abstract] [Full Text] [Related]
6. Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase. Murthy S, Wu M, Bai VU, Hou Z, Menon M, Barrack ER, Kim SH, Reddy GP. PLoS One; 2013 Feb 01; 8(2):e56692. PubMed ID: 23437213 [Abstract] [Full Text] [Related]
7. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Eder IE, Haag P, Basik M, Mousses S, Bektic J, Bartsch G, Klocker H. Mol Carcinog; 2003 Aug 01; 37(4):181-91. PubMed ID: 12891627 [Abstract] [Full Text] [Related]
8. Synchronized prostate cancer cells for studying androgen regulated events in cell cycle progression from G1 into S phase. Cifuentes E, Croxen R, Menon M, Barrack ER, Reddy GP. J Cell Physiol; 2003 Jun 01; 195(3):337-45. PubMed ID: 12704643 [Abstract] [Full Text] [Related]
9. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC. Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234 [Abstract] [Full Text] [Related]
10. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide. Madarová J, Lukesová M, Hlobilková A, Riháková P, Murray PG, Student V, Vojtsek B, Kolár Z. Neoplasma; 2001 Feb 01; 48(5):419-24. PubMed ID: 11845989 [Abstract] [Full Text] [Related]
11. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ. Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223 [Abstract] [Full Text] [Related]
12. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. Prostate; 2008 May 15; 68(7):773-83. PubMed ID: 18247401 [Abstract] [Full Text] [Related]
14. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G. Prostate; 2005 May 01; 63(2):155-68. PubMed ID: 15486991 [Abstract] [Full Text] [Related]
15. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z. Prostate; 2006 Mar 01; 66(4):413-20. PubMed ID: 16302272 [Abstract] [Full Text] [Related]
16. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Chiu FL, Lin JK. Prostate; 2008 Jan 01; 68(1):61-71. PubMed ID: 18008333 [Abstract] [Full Text] [Related]
17. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276 [Abstract] [Full Text] [Related]
18. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Oncogene; 2003 Aug 28; 22(36):5602-13. PubMed ID: 12944908 [Abstract] [Full Text] [Related]
19. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Hara T, Kouno J, Nakamura K, Kusaka M, Yamaoka M. Prostate; 2005 Nov 01; 65(3):268-75. PubMed ID: 16015592 [Abstract] [Full Text] [Related]
20. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791 [Abstract] [Full Text] [Related] Page: [Next] [New Search]